Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial
暂无分享,去创建一个
Dylan L. Steen | M. Sabatine | E. Braunwald | C. Cannon | A. Budaj | D. Morrow | J. Udell | C. Hamm | P. Jarolim | M. O’Donoghue | B. Bergmark | J. Kuder | K. Im | Jianping Guo | P. Jarolím
[1] Menglin Jiang,et al. Elevated fibroblast growth factor-23 and risk of cardiovascular disease or mortality in the general population: A meta-analysis. , 2016, International journal of cardiology.
[2] Danielle M. Enserro,et al. Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study , 2016, Journal of the American Heart Association.
[3] C. Faul,et al. The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy , 2016, Current opinion in nephrology and hypertension.
[4] W. Meng,et al. Klotho inhibits angiotensin II-induced cardiomyocyte hypertrophy through suppression of the AT1R/beta catenin pathway. , 2016, Biochemical and biophysical research communications.
[5] B. Fernández-Fernández,et al. Circulating fibroblast growth factor‐23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease , 2016, Diabetes/metabolism research and reviews.
[6] K. Oh,et al. Sex, Age, and the Association of Serum Phosphorus With All-Cause Mortality in Adults With Normal Kidney Function. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] J. Kautzner,et al. Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure. , 2015, JACC. Heart failure.
[8] W. März,et al. Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction , 2015, Circulation. Heart failure.
[9] K. Mahaffey,et al. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. , 2015, Circulation.
[10] K. Mahaffey,et al. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Heart Failure , 2015 .
[11] M. Wolf,et al. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[12] Solid-Timi Investigators. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014 .
[13] S. Solomon,et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. , 2014, Journal of the American College of Cardiology.
[14] J. Pankow,et al. Fibroblast Growth Factor‐23 and Incident Coronary Heart Disease, Heart Failure, and Cardiovascular Mortality: The Atherosclerosis Risk In Communities Study , 2014, Journal of the American Heart Association.
[15] F. Rodríguez‐Artalejo,et al. Coexistence of Low Vitamin D and High Fibroblast Growth Factor-23 Plasma Levels Predicts an Adverse Outcome in Patients with Coronary Artery Disease , 2014, PloS one.
[16] J. Polak,et al. Fibroblast Growth Factor-23 and Cardiovascular Disease in the General Population: The Multi-Ethnic Study of Atherosclerosis , 2014, Circulation. Heart failure.
[17] A. Go,et al. Fibroblast growth factor-23 and cardiovascular events in CKD. , 2014, Journal of the American Society of Nephrology : JASN.
[18] Kathleen F. Kerr,et al. Testing for improvement in prediction model performance , 2013, Statistics in medicine.
[19] Robert J. Vincent,et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. , 2013, American journal of physiology. Endocrinology and metabolism.
[20] Christiane,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.
[21] E. Ingelsson,et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. , 2013, Kidney international.
[22] B. Dai,et al. A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model , 2012, PloS one.
[23] B. Kestenbaum,et al. Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-living Individuals Chs (cardiovascular Health Study) , 2022 .
[24] S. Moe. Klotho: a master regulator of cardiovascular disease? , 2012, Circulation.
[25] L. Hsiao,et al. Vascular Klotho Deficiency Potentiates the Development of Human Artery Calcification and Mediates Resistance to Fibroblast Growth Factor 23 , 2012, Circulation.
[26] M. Shlipak,et al. Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] D. Fliser,et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. , 2011, European heart journal.
[28] A. Go,et al. FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.
[29] E. Braunwald,et al. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. , 2011, American heart journal.
[30] M. Kuro-o,et al. Klotho deficiency causes vascular calcification in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.
[31] M. Kurabayashi,et al. Association between fibroblast growth factor 23 and left ventricular hypertrophy in maintenance hemodialysis patients. Comparison with B-type natriuretic peptide and cardiac troponin T. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[32] M. Shlipak,et al. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[33] Thomas J. Wang,et al. Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease , 2009, Circulation.
[34] M. Wolf,et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. , 2008, The New England journal of medicine.
[35] L. Quarles,et al. How fibroblast growth factor 23 works. , 2007, Journal of the American Society of Nephrology : JASN.
[36] Y. Takeuchi,et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. , 2004, The Journal of clinical investigation.
[37] K. White,et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.
[38] E. Nabel,et al. Angiotensin-converting enzyme 2--a new cardiac regulator. , 2002, The New England journal of medicine.
[39] M. Nangaku,et al. In Vivo klotho Gene Transfer Ameliorates Angiotensin II-Induced Renal Damage , 2002, Hypertension.
[40] Wolzt,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.
[41] H. Lynch,et al. Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians , 1997 .